Population Genomics Of Plasmodium Vivax In Papua New Guinea
Funder
National Health and Medical Research Council
Funding Amount
$597,238.00
Summary
Plasmodium vivax malaria is a serious global public health problem that has not received the attention it deserves, despite having serious clinical implications and presenting a major problem for regional malaria control programmes. In a study of people living in a malarious area of PNG, we aim to investigate the diversity of natural parasite populations, to better understand the possible effects of malaria control interventions on transmission and human immunity.
The Development Of A Cross-strain And Cross-subtype Pre Pandemic Influenza Vaccine Using Savine Technology
Funder
National Health and Medical Research Council
Funding Amount
$159,500.00
Summary
The flu vaccines in use today work by inducing antibodies to surface proteins. Flu causes disease every year but occasionally a new strain arises that is distincly differnet from previous strains and can cause wides spread disease and deaths worldwide. Our new approach is to increase the level of T cells that can recognise and kill flu infected cells from all flu strains.
Role Of Novel Mobile Elements In The Infiltration Of Antibiotic Resistance Genes Into Clinical Isolates.
Funder
National Health and Medical Research Council
Funding Amount
$421,650.00
Summary
Bacteria have a remarkable ability to capture and spread antibiotic resistance genes. This phenomenon is a particular problem in our hospitals and in the community as multi-drug resistant pathogenic organisms have been selected over time as a result of the use of antibitoics. Moreover the incidence of resistance appears to be on the increase. Once resistant strains appear they can greatly complicate the treatment of infections and the eradication of such pathogens from a hospital is both difficu ....Bacteria have a remarkable ability to capture and spread antibiotic resistance genes. This phenomenon is a particular problem in our hospitals and in the community as multi-drug resistant pathogenic organisms have been selected over time as a result of the use of antibitoics. Moreover the incidence of resistance appears to be on the increase. Once resistant strains appear they can greatly complicate the treatment of infections and the eradication of such pathogens from a hospital is both difficult and costly. We have been working on the problem of how antibiotic resistance genes are spread for a number of years and have identified a novel genetic element that can capture resistance genes by a process of site-specific recombination. This element, the integron, is common in mutli-drug resistant clinical isolates. To be captured by an integron, an antibiotic resistance gene has to be part of a mobile element known as a gene cassette. Although the application of antibiotics acts to amplify pathogens that are resistant and favours their persistance in hospitals, it is generally recognized that neither the gene cassette nor the drug resistance gene evolve in the hospital. Rather, these genes make their way into human pathogens from bacteria that normally reside in other environments, for example soil or water. In this project, we will investigate one route by which drug resistance genes and integrons might find their way into clinically relevant strains and what the sources of the resistance genes and gene cassettes might be. A greater understanding of these processes will help in developing strategies to limit the spread of drug resistant bacteria into and around hospitals.Read moreRead less
A remarkable feature of bacterial cells though is that they can share genes. In so doing bacteria have the ability to acquire completely new characteristics. One example of this spreading of genes is the rapid dissemination of antibiotic resistance in pathogenic bacteria and the creation of multi-resistant superbugs. This process contributes greatly to the problem of hospiatal acquired infeections and results in many patient deaths annually. The other aspect of this sharing of genes is that in a ....A remarkable feature of bacterial cells though is that they can share genes. In so doing bacteria have the ability to acquire completely new characteristics. One example of this spreading of genes is the rapid dissemination of antibiotic resistance in pathogenic bacteria and the creation of multi-resistant superbugs. This process contributes greatly to the problem of hospiatal acquired infeections and results in many patient deaths annually. The other aspect of this sharing of genes is that in a population some cells will lack genes that others have. Some of these shared genes apart from antibiotic resistance can be a concern and include traits that make some bacteria pathogenic. Thus, two cells of the same species may have very different abilities to cause disease based on what additional genes they carry. Genomics is becoming one of the great scientific revolutions of the 21st century. Over 160 microbial genomes have been sequenced to date and from these studies we have also learned many important things including how some bacteria cause disease. Mobile DNA presents unique challenges to microbial genomics however since different individuals in a species can have many different genes. Thus genomics on even many individuals of a species may miss bacterial genes important to us. Here we will be applying genomics in a way that specifically targets those genes that are shared. This will have many benefits. We will be able to greatly increase our rate of discovery of medically important and other genes in way that is targeted. This approach will allow us to discover these shared genes in a way that is much more cost effective and faster than conventional whole cell genomics. It will also allow us to gain an understanding of how benign bacteria associated with humans may act as reservoirs for passing on harmful genes to bacteria that cause hospital infections.Read moreRead less
The Economics Of Reducing The Risk Of Healthcare-acquired Intravascular Device Related Bloodstream Infections
Funder
National Health and Medical Research Council
Funding Amount
$119,500.00
Summary
Approximately one in ten patients will acquire an infection after admission to hospital. Patients will have their hospital stay prolonged during which time they will employ scarce health care resources that might otherwise have been made available to others in need, they will suffer additional pain and anxiety, they will take longer to recuperate after discharge using primary care and outpatient services more intensively and there is a sevenfold increase in the chance of dying in hospital as a r ....Approximately one in ten patients will acquire an infection after admission to hospital. Patients will have their hospital stay prolonged during which time they will employ scarce health care resources that might otherwise have been made available to others in need, they will suffer additional pain and anxiety, they will take longer to recuperate after discharge using primary care and outpatient services more intensively and there is a sevenfold increase in the chance of dying in hospital as a result of an infection. There will be other social costs as those affected take longer to return to their normal economic activities. The aggregate economic burdens imposed by healthcare-associated infection in the US are valued at $AU 11.3 Billion and $AU 3.1 in the UK. Research in currently underway to estimate the economic costs to Australia. One type of hospital infection are those that affect the blood and many are caused by invasive devices. At least 3,500 patients are affected each year in the Australia. The human and financial costs of these particular infections are significant. These infections can be prevented but the preventive activities are costly. The purpose of this research is to systematically evaluate the cost and effectiveness of all known infection control interventions to identify those which offer the best value for money. Furthermore we propose to identify the efficient investment in infection control activities, a point where the economic benefit is equalised with economic cost. This research will identify how much to invest in infection control and the specific interventions to which these investments should be directed. Efficient infection control will save lives, improve outcomes for patients, reduce the period of recuperation, and reduce the significant economic costs to both the patient and the health care system.Read moreRead less
I am an immunologist with a background in virology and peptide chemistry and my work is therefore inter-disciplinary but focused on the design of synthetic, epitope-based vaccines against infectious agents particularly influenza and hepatitis C viruses an
Unravelling The Tetraspanin Web In The Schistosome Tegument.
Funder
National Health and Medical Research Council
Funding Amount
$309,537.00
Summary
Infection with the human blood fluke, Schistosoma mansoni, is a major human ailment affecting almost 200 million people world wide and causing approximately 200 000 deaths per year. Current control efforts rely on anthelminthic drugs but, to sustain their effects, they must be applied for an indefinite period of time due to reinfection. This project will extend recent efforts to develop a vaccine for this organism and decrease the public health burden and mortality associated with infection.
Integration Of Biostatistics And Mathematical Modelling To Improve The Control Of Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$622,655.00
Summary
Improving the control of infectious diseases requires the evaluation of interventions that prevent disease at the population level and successfully treat infections at the individual level. This proposal brings together advanced biostatistical research with mathematical modelling to discover novel methods for evaluating antimalarial treatments and malaria vaccine candidates, leading to new insights in infectious disease control and building capacity in this emerging cross-disciplinary field.
Understanding Pathogenicity And Immunity In An Encephalitic Mouse Model Of Hendra Virus Infection
Funder
National Health and Medical Research Council
Funding Amount
$572,342.00
Summary
Our understanding of Hendra virus infection and immunity is extremely limited and has been hampered by a lack of appropriate animal models of disease and reagents. This Project will employ a newly-established mouse model to study encephalitis, the most life-threatening manifestation of this infection. We will use unique, state-of-the-art infrastructure and a plethora of mouse-specific reagents to investigate the mechanisms involved in regulating the host response to infection.